Press Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 30, 2012H3 Biomedicine to employ Horizon's unique gene editing technology and isogenic cell lines to validate genetically defined drug targets for development of cancer therapeutics
Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, and
-
Apr 19, 2012
Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku...
-
Apr 18, 2012
Eisai Inc. announced today that the results of the study, "Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset...
-
Apr 16, 2012Clinical Study Seeks to Evaluate MORAb-004 plus best supportive care for Extending Progression-Free Survival of Patients with Chemorefractory Metastatic Colorectal Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of...
-
Mar 27, 2012Morphotek®, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian CancerClinical Study Seeks to Evaluate Farletuzumab in Combination with Standard of Care in First-Relapse Patients with Platinum-Sensitive Ovarian Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today it has completed enrollment of the FAR-131 clinical trial. The study is a pivotal Phase 3...